...
首页> 外文期刊>Clinical breast cancer >Breast Cancer Patients Undergoing Sentinel Node Biopsy: Additional Axillary Tumor Burden as a Function of the Total Number of Excised Sentinel Nodes-A Multicenter Study
【24h】

Breast Cancer Patients Undergoing Sentinel Node Biopsy: Additional Axillary Tumor Burden as a Function of the Total Number of Excised Sentinel Nodes-A Multicenter Study

机译:进行前哨淋巴结活检的乳腺癌患者:额外腋窝肿瘤负担与切除前哨淋巴结总数的关系-多中心研究

获取原文
获取原文并翻译 | 示例

摘要

We assessed locoregional relapse, distant metastases, and mortality alongside additional axillary disease in breast cancer patients undergoing sentinel node (SN) biopsy. We included 1070 patients operated for 1090 invasive breast cancers. There were no significant differences between patients with positive or negative SN. The rate of residual axillary disease was dependent on the total number of excised SN. Background: Recent studies have challenged the long-standing assumption that breast cancer prognosis is determined by lymph node regional status. We assessed locoregional relapse, distant metastases, and mortality alongside additional axillary disease in breast cancer patients undergoing sentinel node (SN) biopsy. Patients and Methods: This prospective study assessed 1070 women with clinical T1-T2 invasive breast cancer with negative clinical/ultrasound axillae. Results: A total of 25.1% of patients had positive SN biopsy findings, of whom 69.2% had only 1 involved SN. The rate of axillary recurrence was 0.7%, with no significant differences found between patients with positive or negative SN (0.6% vs. 1.1%). There were also no significant differences in the rate of distant metastases or breast cancere-specific mortality. If we had applied the Z0011 trial suggestions, residual axillary disease would have reached 16.2%: 13.5% in patients over 50% and 21.3% in patients under 50. The rate of residual axillary disease would have been 25.2% in patients with only 1 SN (20.2% in patients over 50% and 38.2% in patients under 50). In patients with 2 SN, residual disease would have ranged from 12.0% in patients over 50% to 19.0% in patients under 50. From 3 SN on, residual disease seems negligible. Conclusion: There were no significant differences in locoregional relapse, distant metastases, or mortality between patients with negative and positive SN. Patients with 3 or more SN have no additional axillary disease. In patients younger 50, one must be extremely cautious if the Z0011 suggestions are to be applied, especially if there is only 1 SN. (C) 2015 Elsevier Inc. All rights reserved.
机译:我们评估了接受前哨淋巴结(SN)活检的乳腺癌患者的局部复发,远处转移和死亡率以及其他腋窝疾病。我们纳入了1070例针对1090例浸润性乳腺癌手术的患者。 SN阳性或阴性的患者之间无显着差异。残留腋窝疾病的发生率取决于所切除的SN总数。背景:最近的研究挑战了长期以来的假设,即乳腺癌的预后由淋巴结区域状态决定。我们评估了接受前哨淋巴结(SN)活检的乳腺癌患者的局部复发,远处转移和死亡率以及其他腋窝疾病。患者与方法:这项前瞻性研究评估了1070名临床T1-T2浸润性乳腺癌的临床/超声腋窝阴性妇女。结果:总共25.1%的患者有SN活检阳性,其中69.2%的患者只有1例涉及SN。腋窝复发率为0.7%,SN阳性或阴性的患者之间无显着差异(0.6%比1.1%)。远处转移或乳腺癌特异性死亡率的发生率也无显着差异。如果我们应用了Z0011试验建议,则残留腋窝疾病将达到16.2%:50%以上的患者为13.5%,50岁以下的患者为21.3%。仅1 SN的患者残留腋窝疾病的比率将为25.2% (50%以上的患者占20.2%,50岁以下的患者占38.2%)。对于2 SN的患者,残留疾病的范围从50%以上的患者的12.0%到50岁以下的患者的19.0%。从3 SN开始,残留的疾病似乎可以忽略不计。结论:SN阴性和阳性的患者在局部复发,远处转移或死亡率方面无显着差异。 SN≥3的患者无其他腋窝疾病。对于50岁以下的患者,如果要应用Z0011建议,必须格外小心,尤其是只有1个SN时。 (C)2015 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号